Thursday, April 12, 2018

International Liver Congress 2018: Early-stage HCV treatment saves money, improves QOL

Related: Liver Congress™ 2018 Scotland: Direct-acting antiviral agent therapy reduces the burden of HCV-related decompensated cirrhosis

Early-stage HCV treatment saves money, improves QOL
April 12, 2018
PARIS — Treating hepatitis C virus in the early stage of disease saves money in drug and medical costs while lowering risk for decompensated cirrhosis, hepatocellular carcinoma, liver transplant and liver-related death, according to a presentation at the International Liver Congress 2018.

“For all these outcomes, the best outcome is experienced by those who started at [fibrosis stage 0 and 1] and the worst by those who have advanced disease,” Scott Johnson, PhD, MHA, an economist with Medicus Economics LLC, said during a press conference. “The advanced patients have ten-sixteenths of the lifespan and quality of life of those who were treated when they were mild.”

Continue reading:

Earlier HCV Tx May Lower Complication Rate, Save Money
PARIS -- Treating patients with hepatitis C virus (HCV) at earlier stages of fibrosis may be reduce both complications and cost, a commercially sponsored modeling study showed here.

There was a lower risk of decompensated cirrhosis, hepatocellular carcinoma, liver transplant, and liver-related death among patients who started treatment at the mild, F0-F1 stage compared to those who started treatment at advanced/compensated cirrhosis (F4/CC).

Continue reading:

No comments:

Post a Comment